Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sorafenib Chemoembolization Evaluation Controlled Trial (SELECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01906216
Recruitment Status : Unknown
Verified August 2019 by Guohong Han, Air Force Military Medical University, China.
Recruitment status was:  Recruiting
First Posted : July 24, 2013
Last Update Posted : August 1, 2019
Sponsor:
Information provided by (Responsible Party):
Guohong Han, Air Force Military Medical University, China

Brief Summary:

This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced hepatocellular carcinoma (HCC) patients compared with sorafenib alone, and to determine the prognostic factors that influence the survival.

Data on the efficacy and safety of sorafenib in combination with TACE in patients with advanced HCC are lacking. Because in western countries, advanced HCC is considered as a contraindication for TACE treatment. However, clinical practice patterns differ markedly between Asia and western countries: in Asia TACE is performed in selected advanced HCC patients. We consider sorafenib combined with TACE could achieve better survival benefit than sorafenib alone in selected advanced HCC patients.


Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Sorafenib Procedure: TACE Phase 2 Phase 3

Detailed Description:

PRIMARY OBJECTIVE:

To compare the overall survival of selected advanced HCC patients treated with sorafenib combined with TACE with sorafenib alone.

SECONDARY OBJECTIVES:

  1. To compare the time to progression(TTP).
  2. To compare the tumor response and disease control rate according to Response Evaluation Criteria in Solid Tumors(RECIST), modified Response Evaluation Criteria in Solid Tumors(mRECIST) and European Association of Liver Disease(EASL) criteria.
  3. To compare the safety.

OTHER OBJECTIVES:

1. To explore the prognostic value of AFP response after treatment.

OUTLINE: This is a multicenter, phase 3, prospective, randomized, controlled trial. Patients are stratified according to

  1. ECOG ( 0 vs. 1)
  2. Child-Pugh (A vs. B7)
  3. Tumor burden

    1. single vs. multiple lesions
    2. tumor size (>8cm vs. ≤8cm)
    3. vascular invasion (yes vs. no)
    4. extrahepatic metastasis (yes vs. no)
  4. Alpha fetoprotein(AFP)(≤ 200 ng/mL vs. > 200 ng/mL) Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Patients undergo the first conventional transarterial chemoembolization (TACE) within 3-7 days after the first administration of sorafenib. The conventional TACE consists of an injection containing a mixture of chemotherapeutic agents (doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels. Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated "on demand" depending on the radiological response.

ARM II: Patients receive two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).

MAINTENANCE THERAPY: Standard follow-up evaluations include contrast-enhanced CT scan and laboratory assessment. Laboratory assessment will be performed every 4 weeks. Radiological follow-up (contrast-enhanced CT scan in liver and chest X-ray) will be performed during week 4 and week 8 after initiation of treatment and thereafter every 8 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial
Study Start Date : September 2013
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Sorafenib

Arm Intervention/treatment
Active Comparator: Sorafenib
All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
Drug: Sorafenib
Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Other Name: Bay 43-9006, Sorafenib (Nexavar®)

Experimental: Sorafenib combined with TACE
Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
Drug: Sorafenib
Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Other Name: Bay 43-9006, Sorafenib (Nexavar®)

Procedure: TACE
The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated "on demand" depending on the radiological response.




Primary Outcome Measures :
  1. Overall survival [ Time Frame: The final analysis will occur when the expected number of death (173 events) is reached. Up to 2.5 years ]
    Overall survival (OS) analysis is measured from the time of randomization until death occurred from any cause.


Secondary Outcome Measures :
  1. Time to progression [ Time Frame: The time to progression will be assessed at the end of the study, up to 2.5 years ]
    The time to progression is measured from the time of randomization to the radiologically confirmed progression.

  2. Tumor response [ Time Frame: Tumor response will be assessed up to 2.5 years ]
    Tumor response will be evaluated according to RECIST, mRECIST and EASL criteria, respectively. Tumor response will be presented in the terms of complete response, partial response, stable disease and progression disease.

  3. Adverse events [ Time Frame: The adverse events will be assessed up to 2.5 years. ]
    The terms and grade of adverse events will be presented according to the Common Terminology Criteria for Adverse Events(CTCAE:version 4.0)


Other Outcome Measures:
  1. AFP response [ Time Frame: The AFP response will be assessed up to 2.5 years. ]
    The clinical laboratory will use the electrochemiluminescence immunoassay method to determine the value of AFP. (Elecsys Cobas e601, Roche) ΔAFP(%) = [(AFPbaseline-AFPpost-treatment)/ AFPbaseline]×100%; AFP response =ΔAFP(%) > AFP response cutoff point



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Prior informed consent
  2. Advanced stage HCC/ Barcelona Clinic Liver Cancer(BCLC) C stage
  3. Confirmed Diagnosis of HCC:

    1. Cirrhotic subjects: Clinical diagnosis by Asian Pacific Association for the Study of the Liver(AASLD) criteria.
    2. Non-cirrhotic subjects: for subjects without cirrhosis, histological or cytological confirmation is mandatory
    3. Documentation of original biopsy for diagnosis is acceptable
  4. Child Pugh class A without ascites or hepatic encephalopathy
  5. Eastern Cooperative Oncology Group(ECOG) Performance Status of 0-1
  6. At least one uni-dimensional lesion measurable by CT-scan or MRI according to the RECIST, mRECIST and EASL criteria,respectively

    1. single lesion>5cm
    2. 2-3 lesions, at least one lesion>3cm if more than 4 lesions, no limitation of the tumor size, but the sum of size of all tumor lesions should be less than 50% of liver parenchyma.
  7. Male or female subjects ≥ 18 years of age
  8. Ability to swallow oral medications
  9. Life expectancy of at least 12 weeks
  10. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial
  11. Adequate bone marrow, liver and renal function as assessed by central lab by means of the following laboratory requirements from samples within 7 days prior to randomization:

    1. Hemoglobin > 9.0 g/dl
    2. Absolute neutrophil count (ANC) >1,500/mm3
    3. Platelet count≥50x109/L
    4. ALB≥28g/L
    5. Total bilirubin < 2 mg/dL
    6. Alanine aminotransferase(ALT) and aspartate aminotransferase(AST) < 5 x upper limit of normal
    7. Blood urea nitrogen(BUN) and creatinine < 1.5 x upper limit of normal
    8. International normalized ratio(INR) < 1.7, or prothrombin time(PT) < 4 seconds above control

Exclusion Criteria:

  1. Diffuse HCC or tumor burden ≥50% of liver parenchyma
  2. Main portal vein obstruction, vascular invasion in hepatic vein or inferior vena cava
  3. Presence of metastasis in biliary tract,brain or bone
  4. Poor blood supply for the liver tumor lesions; poor blood supply refers that the tumor lesions fail to show obvious contrast uptake in the arterial phase and washout in venous or late phases by CT scan or MRI
  5. Any contraindications for hepatic embolization procedures:

    1. Known hepatofugal blood flow
    2. Known porto-systemic shunt
    3. Renal failure / insufficiency requiring hemo-or peritoneal dialysis
  6. Target lesions having previously been treated with local therapy such as resection of HCC, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI)
  7. Other molecular target drugs ongoing or completed < 4 weeks prior to the baseline scan
  8. Prior transarterial embolization or systemic chemotherapy
  9. Any ≥ CTC adverse events(AEs) grade 2 acute toxic effects of any prior local treatment
  10. Patients with untreated varices or active bleeding
  11. History of cardiac disease:

    1. Congestive heart failure >New York Heart Association (NYHA) class 2
    2. Uncontrolled hypertension
  12. Known history of HIV infection
  13. Active clinically serious infections (> grade 2 NCI-CTCAE Version 3.0), except for Hepatitis B virus(HBV) and hepatitis C virus(HCV) infection
  14. Clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug
  15. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug
  16. Previous or concurrent cancer that is distinct in primary site or histology from HCC. Any cancer curatively treated >3 years prior to entry is permitted
  17. Any contraindication for sorafenib or doxorubicin administration
  18. Pregnant or breast-feeding subjects
  19. Any disease(within 6 months of randomization)which could affect the evaluation of the study drug
  20. Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study
  21. Major surgery within 4 weeks prior to start of study drug (e.g. thoracolaparotomy is not allowed, but noninvasive surgery, e.g. biopsy, is allowed)
  22. Autologous bone marrow transplant or stem cell rescue within 1 year prior to start of study drug
  23. History of organ allograft

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01906216


Contacts
Layout table for location contacts
Contact: Guohong Han, MD,PhD +862984771528 guohhan@126.com

Locations
Layout table for location information
China, Shaanxi
Xijing Hospital of Digestive Disease Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Wei Bai, MD    +8615991771343      
Contact: Yan Zhao, MD    +8613571884093      
Sponsors and Collaborators
Air Force Military Medical University, China
Investigators
Layout table for investigator information
Study Chair: Guohong Han, MD,PhD Xijing Hospital of Digestive Disease, Fourth Military Medical University
Principal Investigator: Guohong Han, MD,PhD Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases
Publications:
Layout table for additonal information
Responsible Party: Guohong Han, Professor, Air Force Military Medical University, China
ClinicalTrials.gov Identifier: NCT01906216    
Other Study ID Numbers: XHDD-001
First Posted: July 24, 2013    Key Record Dates
Last Update Posted: August 1, 2019
Last Verified: August 2019
Keywords provided by Guohong Han, Air Force Military Medical University, China:
Hepatocellular carcinoma
sorafenib
transarterial chemoembolization
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Sorafenib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action